DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Schnyder corneal dystrophy — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSchnyder corneal dystrophy maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for schnyder corneal dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glutathione S-transferase mu 1 (GSTM1) — GSTM1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gshdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1XW6 · 1.9 Å · ligand Glutathione (GSH). Experimental structure, not a prediction.
What the evidence adds up to
In a long-term cohort study of two unrelated families with Schnyder corneal dystrophy, examined in 1975 and again in 1984, corneal opacities never regressed. Progression was more frequent in diffuse opacities than in crystalline opacities. Both types reappeared and progressed after penetrating keratoplasty. Mean cholesterol levels in carriers were above normal; six had a moderate type IIa dyslipoproteinemia, while two carriers had low apo B. The degree of corneal opacification showed no relationship to dyslipoproteinemia. The authors concluded that Schnyder corneal dystrophy appears to involve only corneal lipid metabolism and not to be a systemic disease.
Two patients with disabling visual acuity from Schnyder crystalline corneal dystrophy were treated with excimer laser phototherapeutic keratectomy (PTK). The patient with the crystalline form improved from a best corrected visual acuity (BCVA) of 20/70 to 20/25. The patient with the sine crystals form improved from 20/70 to 20/30. The authors concluded that PTK is a valuable tool in treating the crystalline form. No data on long-term durability of this visual improvement, recurrence rates after PTK, or comparison with untreated eyes were provided in this report.
A separate study compared confocal microscopy images of corneal dystrophies, including Schnyder dystrophy, using a slit scanning microscope versus a laser scanning microscope. Both devices provided helpful diagnostic findings about corneal microstructure, and no essential qualitative differences between the images were observed. The study did not report any treatment or outcome data.
What is still missing is any controlled trial of PTK versus no treatment or other interventions, long-term follow-up data on recurrence and visual stability after PTK, and any pharmacological approach to the underlying corneal lipid deposition. No therapy has been shown to halt progression or prevent recurrence after keratoplasty. Patient stratification by crystalline versus non-crystalline form, and by systemic lipid profile, has not been used to guide treatment decisions in a prospective trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ophthalmic Paediatrics and Genetics · 1986 · 49 citations
Schnyder's dystrophy Progression and metabolism
AbstractIn the first long-term cohort study of Schnyder's corneal dystrophy the authors examined affected and unaffected members of two unrelated families in 1975 and 1976 respectively, and again in 1984. They identified carriers, catalogued changes in the diffuse and crystalline corneal opacities which characterize this dystrophy and analysed the patient's lipid metabolism. Corneal opacities never regressed. Progression was more frequent in diffuse than in crystalline opacities. Both crystalline and diffuse opacities reappeared and progressed following penetrating keratoplasty. Mean cholesterol levels in the carrier group were above normal and six had a moderate type IIa dyslipoproteinemia; conversely, two carriers had low apo B. The degree of corneal opacification showed no relationship to dyslipoproteinemia. Schnyder's corneal dystrophy appears to involve the corneal lipid metabolism only and not to be a systemic disease.
Klinische Monatsblätter für Augenheilkunde · 2006 · 10 citations
Konfokale Scanning-Mikroskopie: Eine vergleichende Darstellung von Hornhautdystrophiebefunden mittels ConfoScanP2 und Rostock Cornea Modul-HRT II
AbstractBACKGROUND: The object of this work was a comparison of confocal images of corneal dystrophies made by a slit scanning microscope versus a laser scanning microscope. MATERIAL AND METHODS: Using the Rostock Cornea Modul-HRT II as a confocal laser scanning microscope the images of five patients with some epithelial, stromal and endothelial corneal dystrophies were acquired. The pictures were compared qualitatively with those taken by the slit scanning microscope "ConfoScan P2" from corresponding pathologies. Also, the images of normal corneas of ten healthy persons were acquired for a qualitative comparison. RESULTS: Confocal images from both devices were able to provide significant helpful diagnostic findings about the corneal microstructure. Essential qualitative differences between the images of both devices used were not observed. Due to the additional hardware components and the software module for image acquisition, analysis and archiving, the RCM-HRT II is favoured over the "ConfoScan P2". Nevertheless, the evaluation in favour of the RCM-HRT II has to be confined because an optimised, user-friendly enhancement, the "ConfoScan 4" is currently available. CONCLUSION: Evaluating corneal dystrophies in vivo, an equivalent utility of both technical approaches has been observed.
Klinische Monatsblätter für Augenheilkunde · 1998 · 7 citations
Die Möglichkeiten der therapeutischen Photokeratektomie mit dem Excimerlaser bei der Behandlung der Schnyder kristallinen Hornhautdystrophie
AbstractPURPOSE: To evaluate the efficacy of excimer laser phototherapeutic keratectomy (PTK) in treating the Schnyder cristalline corneal dystrophy. METHODS: We examined the members of three generations of a family affected by Schnyder crystalline dystrophy. Two patients with disabling visual acuity were treated with PTK. RESULTS: The best corrected visual acuity (BCVA) of the patient with the cristalline form of the dystrophy progressed from 20/70 to 20/25. The BCVA of the other patient affected by the sine crystals form of the Schnyder dystrophy progressed from 20/70 to 20/30. CONCLUSIONS: Excimer laser photokeratectomy is a valuable tool in treating the Schnyder cristalline form of corneal dystrophy.
In vivo confocal microscopy as a diagnostic tool in Schnyder Corneal Dystrophy’s case
AbstractAbstract Schnyder’s corneal dystrophy (SCD) is a rare corneal condition characterized by cholesterol and phospholipids deposition in the stroma and Bowman’s layer. We present a case report of a patient who had a progressive corneal stromal haze in both eyes since he was 15 years old. Etiological diagnosis of SCD was well established by In Vivo Confocal Microscopy (IVCM).
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
